Accendatech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2.8M

Overview

Accendatech USA Inc., founded in 2017, is a clinical-stage biotech developing ACT001, a drug candidate for treating glioblastoma and DIPG, a rare pediatric brain tumor. The company has completed Phase 1 clinical trials for ACT001 and is advancing its development. As a subsidiary of the publicly-traded Accendatech Co. Ltd. in China, it leverages its parent company's research while establishing a U.S. operational base in Houston, Texas, to drive clinical development and partnerships.

OncologyCentral Nervous System

Technology Platform

Small molecule drug development focused on targeting brain tumors, potentially involving anti-cancer stem cell mechanisms.

Funding History

1

Total raised:$2.8M

Seed$2.8MUndisclosedSep 15, 2020

Opportunities

The significant unmet medical need in aggressive brain cancers like GBM and DIPG creates a substantial market for effective new therapies.

Success in clinical development, particularly for the rare pediatric DIPG indication, could qualify for Orphan Drug Designation, providing regulatory and commercial advantages.

Risk Factors

Extreme binary risk as the company's value is tied to a single clinical-stage asset (ACT001) with a high probability of failure inherent in drug development.

Operational risks include a lack of visible leadership and potential complexities in its cross-Pacific corporate structure with its Chinese parent company.

Competitive Landscape

The neuro-oncology space is highly competitive, with numerous biotech and pharmaceutical companies pursuing novel therapies for GBM, including immunotherapies, targeted therapies, and novel drug delivery systems. Accendatech's small molecule approach will need to demonstrate clear efficacy and safety advantages over existing and emerging treatments.

More companies in Small Molecule Drugs →More companies in United States →